CD38 and plasma cell myeloma: There is now substantial evidence for the additional benefit of anti‐CD38 monoclonal antibody treatment when added to anti‐myeloma therapy from multiple trials in the frontline (MAIA, CASSIOPEIA, GRIFFIN) [10, 11, 12] and relapsed settings (CASTOR and POLLUX) [13, 14].